Related Experiment Video

Updated: May 22, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Novel lipid-based approaches to pediatric intestinal failure-associated liver disease

Ivan R Diamond1, Paul B Pencharz, Brian M Feldman

  • 1Child Health Evaluative Sciences Program, The Hospital for Sick Children, Toronto, Ontario, Canada.

Archives of Pediatrics & Adolescent Medicine
|May 9, 2012
PubMed

Insights

New strategies for preventing intestinal failure-associated liver disease (IFALD) in children show promise but lack definitive evidence. Current data is insufficient to support novel lipid therapies as standard care for early-stage IFALD.

Area of Science:

  • Pediatric Gastroenterology
  • Hepatology
  • Nutritional Support

Background:

  • Intestinal failure-associated liver disease (IFALD) is a major cause of morbidity in children with intestinal failure.
  • Intravenous lipid emulsions are implicated in IFALD development, prompting research into alternatives.
  • Current management focuses on addressing multifactorial causes of IFALD.

Purpose of the Study:

  • To examine the rationale and current evidence for alternative intravenous lipid strategies in children with IFALD.
  • To assess the efficacy and safety of lipid minimization and alternative lipid emulsions (including ω-3 fatty acids).
  • To determine if novel therapies are suitable for standard care in preventing IFALD progression.

Main Methods:

  • Review of existing literature on lipid minimization and alternative intravenous lipid emulsions.
  • Analysis of studies focusing on children with intestinal failure and IFALD.
  • Evaluation of evidence from uncontrolled settings, primarily in advanced IFALD cases.

Main Results:

  • Alternative approaches like lipid minimization and ω-3 fatty acid emulsions show potential.
  • Studies are predominantly uncontrolled and focus on children with advanced IFALD.
  • Lack of definitive evidence regarding the efficacy of these novel therapies.

Conclusions:

  • Insufficient evidence exists to support novel lipid therapies as standard of care for preventing IFALD progression in children with no or early IFALD.
  • Further research is needed to evaluate the efficacy and safety, including effects on growth and development.
  • Current data does not support widespread adoption of these therapies beyond specific clinical contexts.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Lipid Digestion01:06

Lipid Digestion

Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.